Cannes canceled: Lions creative ad festival, including Lions Health, called off amid COVID-19 tumult

Flags outside Cannes Palais II at Cannes Lions Health 2019
The Cannes Lions Health awards and event are canceled for 2020 amid turmoil caused by COVID-19. (Beth Snyder Bulik)

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out or were seriously considering it.

While a virtual festival was reportedly considered, organizers decided to close the show for the year and look ahead to the next one in June 2021. Cannes Lions, which includes Lions Health specific to the pharma and healthcare industry, initially postponed the conference and awards show two week ago.

Friday, organizers said the impact from COVID-19 on the marketing, media and creative industries required the agencies’ attention elsewhere.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

“It has become clear to us our customers’ priorities have shifted to the need to protect people, to serve consumers with essential items and to focus on preserving companies, society and economies,” the hosts said in a news release.

RELATED: Looking back at Lions Health: Fighting for great creative, new ad formats, more competitors

The event, begun in the 1950s, draws more than 10,000 people from ad agencies and brand marketers from 90 countries around the world to the south of France for a week. Lions Health, the pharma and healthcare track established in 2014, runs for the first two days of the event.

The Cannes Lions cancellation joins scores of other professional and medical conferences called off amid COVID-19 travel restrictions, financial pressures and attendee considerations.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.